According to a Tufts University study commissioned by Thermo Fisher Scientific, the company’s Accelerator solutions integrating CRO and CDMO services reduce cancer drug development timelines by up to 34 months. The model minimizes delays between trial phases by consolidating management and accountability, expediting regulatory and clinical processes. Executives anticipate applicability beyond oncology, bolstering efficiency for complex therapeutic modalities across indications.